2019
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. Journal For ImmunoTherapy Of Cancer 2019, 7: 172. PMID: 31291990, PMCID: PMC6617639, DOI: 10.1186/s40425-019-0643-8.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsEGFR-mutant lung cancerMutant lung cancerTumor regressionErlotinib treatmentLung cancerImmune cellsLung tumorsMouse modelEffects of TKIsGrowth factor receptor tyrosine kinase inhibitorsTumor-infiltrating immune cellsDrug resistanceReceptor tyrosine kinase inhibitorsInflammatory immune cellsInflammatory T cellsEffect of erlotinibEGFR mutant lung tumorsInflammatory cellsImmunological profileT cellsCD40 agonistsImmunostimulatory effectsAlveolar macrophagesErlotinib
1993
T cell unresponsiveness correlates with quantitative TCR levels in a transgenic model
Homer R, Mamalaki C, Kioussis D, Flavell R. T cell unresponsiveness correlates with quantitative TCR levels in a transgenic model. International Immunology 1993, 5: 1495-1500. PMID: 7906139, DOI: 10.1093/intimm/5.12.1495.Peer-Reviewed Original Research
1985
Genetic, Serological and Functional Analysis of I‐J Molecules
Murphy D, Horowitz M, Homer R, Flood P. Genetic, Serological and Functional Analysis of I‐J Molecules. Immunological Reviews 1985, 83: 79-103. PMID: 3160653, DOI: 10.1111/j.1600-065x.1985.tb00471.x.Peer-Reviewed Original Research